Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.
Pyoderma gangrenosum and hidradenitis suppurativa are skin conditions characterized by an intense neutrophil-mediated inflammatory response that is often difficult to effectively treat. Successful use of interleukin (IL)-1β inhibition using canakinumab and anakinra has been reported in patients with...
| Publicado en: | Journal of Clinical & Aesthetic Dermatology Vol. 10; no. 9; pp. 36 - 39 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Matrix Medical Communications, LLC
Sep2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Pyoderma gangrenosum and hidradenitis suppurativa are skin conditions characterized by an intense neutrophil-mediated inflammatory response that is often difficult to effectively treat. Successful use of interleukin (IL)-1β inhibition using canakinumab and anakinra has been reported in patients with concomitant pyoderma gangrenosum and hidradenitis suppurativa. We report two cases where targeted therapy with canakinumab failed to lead to improvement for patients with pyoderma gangrenosum and hidradenitis suppurativa. The reason behind the non-response to IL-1β blockade seen in these patients is unclear. Our report suggests that further controlled studies are warranted to help clinicians predict treatment responses to anti-IL-1 therapies in these challenging patients. |
|---|